Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

68 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Application of modern spatio-temporal analysis technologies to identify and visualize patterns of rabies emergence among different animal species in Kazakhstan.
Mukhanbetkaliyeva AA, Kabzhanova AM, Kadyrov AS, Mukhanbetkaliyev YY, Bakishev TG, Bainiyazov AA, Tleulessov RB, Korennoy FI, Perez AM, Abdrakhmanov SK. Mukhanbetkaliyeva AA, et al. Among authors: kadyrov as. Geospat Health. 2024 Jul 31;19(2). doi: 10.4081/gh.2024.1290. Geospat Health. 2024. PMID: 39221839 Free article.
Experiences in the introduction of bedaquiline pretomanid linezolid for drug-resistant tuberculosis in Kyrgyzstan.
Myrzaliev B, Ahmatov M, Duishekeeva A, Kulzhabaeva A, Kadyrov A, Toktogonova A, Abdulaeva G, Wares DF, Mirtskhulava V, Mbenga M, Slyzkyi A, Foraida S, Diachenko M, Juneja S, Turdumambetova G, Musaeva A, Gebhard A. Myrzaliev B, et al. Among authors: kadyrov a. J Clin Tuberc Other Mycobact Dis. 2024 Jul 26;36:100472. doi: 10.1016/j.jctube.2024.100472. eCollection 2024 Aug. J Clin Tuberc Other Mycobact Dis. 2024. PMID: 39175915 Free PMC article.
Effectiveness and safety of modified fully oral 9-month treatment regimens for rifampicin-resistant tuberculosis: a prospective cohort study.
Korotych O, Achar J, Gurbanova E, Hovhannesyan A, Lomtadze N, Ciobanu A, Skrahina A, Dravniece G, Kuksa L, Rich M, Khachatryan N, Germanovych M, Kadyrov A, Terleieva I, Akhundova I, Adenov M, Durdyeva M, Kiria N, Parpieva N, Yatskevich N, Jumayev R, Nurov R, Diktanas S, Vilc V, Migliori GB, Yedilbayev A. Korotych O, et al. Among authors: kadyrov a. Lancet Infect Dis. 2024 Oct;24(10):1151-1161. doi: 10.1016/S1473-3099(24)00228-7. Epub 2024 Jun 13. Lancet Infect Dis. 2024. PMID: 38880112 Free PMC article.
Time to Treatment and Risk Factors for Unsuccessful Treatment Outcomes among People Who Started Second-Line Treatment for Rifampicin-Resistant or Multi-Drug-Resistant Tuberculosis in the Kyrgyz Republic, 2021.
Kyrbashov B, Kulzhabaeva A, Kadyrov A, Toktogonova A, Timire C, Satyanarayana S, Istamov K. Kyrbashov B, et al. Among authors: kadyrov a. Trop Med Infect Dis. 2023 Aug 10;8(8):407. doi: 10.3390/tropicalmed8080407. Trop Med Infect Dis. 2023. PMID: 37624346 Free PMC article.
68 results